
Blood cancer patients most susceptible to a potentially fatal side effect of immunotherapy called neurotoxicity could be identified by looking for specific markers, according to a new US study.
The team, from the Fred Hutchinson Cancer Research Centre, identified a number of potential biomarkers that could help doctors identify those most at risk of damage to the brain or nervous system (neurotoxicity) after CAR T cell therapy.
“This type of research is important because the cause of the neurotoxicity in these patients is not well understood.”- Dr Martin Pule, Cancer Research UK
Researchers who led the study, published in Cancer Discovery, said that while the specific type of T cell therapy tested, called CD19 CAR T cell therapy, can be “highly effective” the side effects need to be better understood.
Source: Cancer Research UK







